ALK and anaplastic large cell lymphoma: In a phase 2 clinical trial of alectinib for the treatment of R/R ALK+ ALCL(Range, 6-70 years), the ORR after alectinib treatment was 80% and the CR rate was 60%, while the 1-year PFS, event-free survival (EFS), and overall survival (OS) rates were 58.3%, 70.0%, and 70.0% respectively (47).